# Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN

> **NCT03613532** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Jacqueline Garcia, MD** · enrollment: 102 (actual)

## Conditions studied

- Acute Myeloid Leukemia (AML)
- Myelodysplastic Syndrome (MDS)
- Chronic Myelomonocytic Leukemia (CMML)
- MDS/Myeloproliferative Neoplasm-unclassifiable (MDS/MPN-unclassifiable)
- Hematopoietic Stem Cell Transplant

## Interventions

- **DRUG:** Venetoclax
- **DRUG:** Fludarabine
- **DRUG:** Busulfan
- **DRUG:** Venetoclax
- **DRUG:** Azacitidine
- **DRUG:** Decitabine/cedazuridine

## Key facts

- **NCT ID:** NCT03613532
- **Lead sponsor:** Jacqueline Garcia, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-10-24
- **Primary completion:** 2026-05-01
- **Final completion:** 2027-03-01
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2025-12-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03613532

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03613532, "Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT03613532. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*